Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
Head-to-head evidence comparison — which supplement is right for you?
Piracetam and SAMe are closely matched across evidence, studies, and safety.
Verdict
Likely helps
4 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
0 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Piracetam and SAMe have evidence — compare verdict strength side-by-side.
1200-4800mg daily in divided doses
Divided into 2-3 doses, Morning and early afternoon, With a choline source
Piracetam powder or capsules
400-1600mg for mood; 600-1200mg for joints
On empty stomach, Morning and/or midday
Enteric-coated tablets (SAMe tosylate or butanedisulfonate)
2-4 weeks
1-2 weeks
Ongoing
First few days
2-6 weeks
4-8 weeks
4-8 weeks
The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis
Psychopharmacology (2018) · Meta analysis · n=44854
The pooled standardized mean difference of the treatment effects on cognitive dysfunction was 0.439 (95% confidence interval 0.374, 0.504).
Piracetam for reducing the incidence of painful sickle cell disease crises
The Cochrane database of systematic reviews (2016) · Meta analysis · n=169
Although there was no significant difference between the piracetam and placebo periods for the number of days of hospitalisation (P = 0.87) in one trial, inconsistencies in the criteria necessary for hospitalisation during sickle crises did not permit accurate conclusions to be drawn.
Treatment Efficacy of Pharmacotherapies for Frontotemporal Dementia: A Network Meta-Analysis of Randomized Controlled Trials
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry (2023) · Meta analysis · n=243
Compared with placebo, high-dose oxytocin (72 international units) was associated with the greatest improvement in patients' neuropsychiatric symptoms (SMD = -1.17, 95% CIs = -2.25 to -0.08, z = -2.10, p = 0.035).
S-Adenosylmethionine for osteoarthritis of the knee or hip
The Cochrane database of systematic reviews (2009) · Meta analysis · n=656
For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I(2) = 0).
Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta-Analysis
Neuropsychopharmacology reports (2025) · Meta analysis · n=1049
A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88).
S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review
Nutrients (2024) · Systematic review · n=15
The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement.
Based on meta-analysis of 1002 stroke patients, but showed non-significant increase in death at one month. Evidence is limited and mixed. Conservative effectiveness estimates due to safety concerns.
Meta-analysis of 656 patients showed small effect size (SMD -0.17) corresponding to only 0.4cm improvement on 10cm pain scale. Effect is modest and barely reaches statistical significance threshold.
AI-estimated from published studies. Interpret as directional guidance.
Both Piracetam and SAMe are closely matched — the best choice depends on your specific health goals.
For sharpen focus, Piracetam has a higher relevance score (75 vs 42).
No known interactions between Piracetam and SAMe have been documented in our database. However, always consult a healthcare provider before combining supplements.